Morning Overview on MSN
A targeted drug won approval for a hard-to-treat form of advanced prostate cancer
Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...
A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...
Proceeds will fund advancement of ARON degrader, FX-111, to proof of concept and preclinical development of ARON RIPTAC program- Veteran ...
The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway ...
- Fundingwill support Phase 1b/2a clinical trial of MVB-101, a prostate-specific membrane antigen x folate receptor alpha (PSMA x FRα) targeted drug conjugate - - Exclusive license to MVB-101, ...
Daniel George, MD, Director of Genitourinary Oncology at Duke Cancer Institute and investigator for the CAPItello-281 trial, said: “Patients with PTEN-deficient metastatic hormone-sensitive prostate ...
Urological tumors, including prostate cancer and urothelial carcinomas, remain major contributors to global cancer morbidity and mortality. Despite recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results